Immunocore Announces Appointment of Eva-Lotta Allan to the Board
News May 02, 2013
Immunocore Limited announced the appointment of Eva-Lotta Allan to the Board as Chief Business Officer. This is a new position, which has been created to strengthen the company’s management team as Immunocore continues to expand its operations. Ms Allan will join Immunocore on 7 May 2013.
Immunocore has created a world-leading T cell receptor technology which exploits the power of the body’s own immune system to find and kill diseased cells. The company is developing a portfolio of products from the platform, called ImmTACs, for the treatment of cancer, chronic infectious disease and diabetes. The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in clinical trials in the UK and USA.
Eva-Lotta Allan brings over two decades of business development experience from the biotechnology and life science industry and joins from Ablynx NV, where she served as Chief Business Officer since 2006. She was a key contributor to Ablynx’s transformation from a small private platform company to a significant public biotechnology company with an impressive pipeline and partnerships. In her role as Ablynx’s CBO, she closed a number of deals of significant value, with premier pharmaceutical companies bringing in over €160 million in non-dilutive cash to the company. Prior to Ablynx, Ms Allan was Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. She received her degree in microbiology from the University of Stockholm.
James Noble, Immunocore’s Chief Executive Officer, said: “I am pleased to welcome Eva-Lotta to our senior Management team and Board of Directors at this critical point for Immunocore as we expand and develop our pipeline of products. She brings with her a wealth of knowledge and experience in business development.”
Eva-Lotta Allan commented on her appointment: “I am delighted to be joining Immunocore at this exciting time. I have been impressed by the quality of the science and unique and broad application of ImmTACs in cancer. I look forward to working with the Immunocore team and to establishing strategically important collaborations.”
Researchers Uncover Muscle Growth Inhibitor Activation Mechanism Aiding ALS Treatment EffortsNews
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for limiting muscle, is activated.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.